간행물

Journal of Gynecologic Oncology (JGO) update

  • : 대한부인종양학회(구 대한부인종양·콜포스코피학회)
  • : 의약학분야  >  산부인과학
  • : KCI등재
  • : SCI,SCOPUS
  • : 연속간행물
  • : 격월
  • : 2005-0380
  • : 2005-0399
  • : 대한부인종양.콜포스코피학회잡지(~2004)→부인종양(2005~)→Journal of Gynecologic Oncolgy (JGO)(2008~)

수록정보
수록범위 : 1권1호(1990)~31권1호(2020) |수록논문 수 : 1,542
Journal of Gynecologic Oncology (JGO)
31권1호(2020년 01월) 수록논문
최근 권호 논문
| | | |

KCI등재 SCI SCOPUS

1The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy

저자 : Koray Aslan , Mehmet Mutlu Meydanli , Murat Oz , Yusuf Aytac Tohma , Ali Haberal , Ali Ayhan

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-13 (13 pages)

다운로드

(기관인증 필요)

초록보기

Objective: The aim of this study was to determine the prognostic value of lymph node ratio (LNR) in women with 2018 International Federation of Gynecology and Obstetrics stage IIIC cervical cancer.
Methods: In this retrospective dual-institutional study, a total of 185 node-positive cervical cancer patients who had undergone radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy were included. All of the patients received adjuvant chemoradiation after surgery. LNR was defined as the ratio of positive lymph nodes (LNs) to the total number of LNs removed. The patients were categorized into 2 groups according to LNR; LNR <0.05 and LNR ≥0.05. The prognostic value of LNR was evaluated with univariate log-rank tests and multivariate Cox regression models.
Results: A total of 138 patients (74.6%) had stage IIIC1 disease and 47 (25.4%) patients had stage IIIC2 disease. With a median follow-up period of 45.5 months (range 3-135 months), the 5-year disease-free survival (DFS) rate was 62.5% whereas the 5-year overall survival (OS) rate was 70.4% for the entire study population. The 5-year DFS rates for LNR <0.05 and LNR ≥0.05 were 78.2%, and 48.4%, respectively (p<0.001). Additionally, the 5-year OS rates for LNR <0.05 and LNR ≥0.05 were 80.6%, and 61.2%, respectively (p=0.007). On multivariate analysis, LNR ≥0.05 was associated with a worse DFS (hazard ratio [HR]=2.12; 95% confidence interval [CI]=1.15-3.90; p=0.015) and OS (HR=1.95; 95% CI=1.01-3.77; p=0.046) in women with stage IIIC cervical cancer.
Conclusions: LNR ≥0.05 seems to be an independent prognostic factor for decreased DFS and OS in stage IIIC cervical carcinoma.

KCI등재 SCI SCOPUS

2Japan Society of Gynecologic Oncology 2018 guidelines for treatment of uterine body neoplasms

저자 : Wataru Yamagami , Mikio Mikami , Satoru Nagase , Tsutomu Tabata , Yoichi Kobayashi , Masanori Kaneuchi , Hiroaki Kobayashi , Hidekazu Yamada , Kiyoshi Hasegawa , Hiroyuki Fujiwara , Hidetaka Katabuchi , Daisuke

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-21 (21 pages)

다운로드

(기관인증 필요)

초록보기

The Fourth Edition of the Guidelines for Treatment of Uterine Body Neoplasm was published in 2018. These guidelines include 9 chapters: 1. Overview of the guidelines, 2. Initial treatment for endometrial cancer, 3. Postoperative adjuvant therapy for endometrial cancer, 4. Post-treatment surveillance for endometrial cancer, 5. Treatment for advanced or recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment of uterine carcinosarcoma and uterine sarcoma, 8. Treatment of trophoblastic disease, 9. Document collection; and nine algorithms: 1-3. Initial treatment of endometrial cancer, 4. Postoperative adjuvant treatment for endometrial cancer, 5. Treatment of recurrent endometrial cancer, 6. Fertility-sparing therapy, 7. Treatment for uterine carcinosarcoma, 8. Treatment for uterine sarcoma, 9. Treatment for choriocarcinoma. Each chapter includes overviews and clinical questions, and recommendations, objectives, explanation, and references are provided for each clinical question. This revision has no major changes compared to the 3rd edition, but does have some differences: 1) an explanation of the recommendation decision process and conflict of interest considerations have been added in the overview, 2) nurses, pharmacists and patients participated in creation of the guidelines, in addition to physicians, 3) the approach to evidence collection is listed at the end of the guidelines, and 4) for clinical questions that lack evidence or clinical validation, the opinion of the Guidelines Committee is given as a “Recommendations for tomorrow”.

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCI SCOPUS

4High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology

저자 : Tae-wook Kong , Miseon Kim , Young-han Kim , Yong Beom Kim , Jayeon Kim , Jae-weon Kim , Mi Hye Park , Joo Hyun Park , Jeong Ho Rhee , Myong Cheol Lim , Joon-seok Hong

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-10 (10 pages)

다운로드

(기관인증 필요)

초록보기

Based on emerging data and current knowledge regarding high-risk human papillomavirus (hrHPV) testing as a primary screening for cervical cancer, the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology support the following scientific facts:
• Compared to cytology, hrHPV screening has higher sensitivity and detects more cases of high-grade cervical intraepithelial neoplasia.
• Qualified hrHPV testing can be considered as an alternative primary screening for cervical cancer to the current cytology method.
• The starting age of primary hrHPV screening should not be before 25 years because of possible overtreatment in this age, which has a high human papillomavirus (HPV) prevalence but rarely progresses to cancer. The screening interval should be no sooner than every 3 years and no longer than every 5 years.
• Before the introduction of hrHPV screening in Korea, research into comparative effectiveness of primary hrHPV screening for cervical cancer should be conducted to determine the appropriate HPV assay, starting age, and screening interval.

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCI SCOPUS

6The basic principles of oncologic surgery during minimally invasive radical hysterectomy

저자 : Christhardt Köhler , Achim Schneider , Simone Marnitz , Andrea Plaikner

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-4 (4 pages)

다운로드

(기관인증 필요)

키워드 보기
초록보기

KCI등재 SCI SCOPUS

7Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery

저자 : Ying L Liu , Olga T Filippova , Qin Zhou , Alexia Iasonos , Dennis S Chi , Oliver Zivanovic , Yukio Sonoda , Ginger J Gardner , Vance A Broach , Roisin E O Cearbhaill , Jason A Konner , Carol Aghajanian , K

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-12 (12 pages)

다운로드

(기관인증 필요)

초록보기

Objective: Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) confers similar outcomes as primary debulking surgery and chemotherapy. Little is known about patients who receive NACT but do not undergo debulking surgery. Our aim was to characterize these patients.
Methods: We prospectively identified patients with newly diagnosed stage III/IV ovarian cancer treated with NACT from 7/1/15-12/1/17. Fisher exact and Wilcoxon rank-sum tests were used to compare clinical characteristics by surgical status. The Kaplan-Meier method was used to estimate survival outcomes. Log-rank test and Cox proportional hazards model were applied to assess the relationship of covariates to outcome, and time-dependent covariates were applied to variables collected after diagnosis.
Results: Of 224 women who received NACT, 162 (72%) underwent IDS and 62 (28%) did not undergo surgery. The non-surgical group was older (p<0.001), had higher Charlson comorbidity index (CCI; p<0.001), lower albumin levels (p=0.007), lower Karnofsky performance scores (p<0.001), and were more likely to have dose reductions in NACT (p<0.001). Reasons for no surgery included poor response to NACT (39%), death (15%), comorbidities (24%), patient preference (16%), and loss to follow-up (6%). The no surgery group had significantly worse overall survival (OS) than the surgery group (hazard ratio=3.34; 95% confidence interval=1.66-6.72; p<0.001), after adjustment for age, CCI, and dose reductions.
Conclusions: A significant proportion of women treated with NACT do not undergo IDS, and these women are older, frailer, and have worse OS. More studies are needed to find optimal therapies to maximize outcomes in this high-risk, elderly population.

KCI등재 SCI SCOPUS

8Comparison of rivaroxaban and dalteparin for the long-term treatment of venous thromboembolism in patients with gynecologic cancers

저자 : Jang Ho Lee , Joo Hee Lee , Kyung-wook Jo , Jin-won Huh , Yeon-mok Oh , Jae Seung Lee

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-10 (10 pages)

다운로드

(기관인증 필요)

초록보기

Objectives: Two randomized, controlled studies comparing outcomes in patients treated with direct oral anticoagulants or low-molecular weight heparin for cancer-associated venous thromboembolism (VTE) have previously been performed. However, gynecologic cancers accounted for approximately 10% of the study populations. We compared the outcomes of patients with primary gynecological cancers who were treated for cancer-associated VTE with either rivaroxaban or dalteparin.
Methods: The 162 eligible patients with gynecologic cancers who were treated with either dalteparin (n=60) or rivaroxaban (n=102) were reviewed. The primary outcome was a composite event, which included recurrence or clinically relevant bleeding events during the therapeutic period. Secondary outcomes were recurrence, clinically relevant bleeding events, and mortality.
Results: During the therapeutic period, there were no significant differences between the groups in the proportion of composite events, recurrence, or clinically relevant bleeding. Multivariate analysis using the Cox proportional hazards model also showed no significant difference in the number of composite events and clinically relevant bleeding between the groups. In the rivaroxaban group, 44.0% of patients experienced gastrointestinal bleeding and 24.0% experienced urinary tract bleeding. In the dalteparin group, bleeding was most common in the urinary tract (44.4%) and at the injection site (22.2%).
Conclusion: In this study, although there were no significant differences in effectiveness or safety between the rivaroxaban and dalteparin groups, rivaroxaban use was associated with a higher rate of clinically relevant bleeding than dalteparin. Therefore, caution should be taken when prescribing rivaroxaban for gynecologic cancer-associated VTE and bleeding events should be carefully monitored.

KCI등재 SCI SCOPUS

9An optimized BRCA1/2 next-generationsequencing for different clinical sample types

저자 : Yoonjung Kim , Chi-heum Cho , Jung-sook Ha , Do-hoon Kim , Sun Young Kwon , Seoung Chul Oh , Kyung-a Lee

발행기관 : 대한부인종양학회(구 대한부인종양·콜포스코피학회) 간행물 : Journal of Gynecologic Oncology (JGO) 31권 1호 발행 연도 : 2020 페이지 : pp. 1-14 (14 pages)

다운로드

(기관인증 필요)

초록보기

Objective: A simultaneous detection of germline and somatic mutations in ovarian cancer (OC) using tumor materials is considered to be cost-effective for BRCA1/2 testing. However, there are limited studies of the analytical performances according to various sample types. The aim of this study is to propose a strategy for routine BRCA1/2 next-generation sequencing (NGS) screening based on analytical performance according to different sample types.
Methods: We compared BRCA1/2 NGS screening assay using buffy coat, fresh-frozen (FF) and formalin-fixed paraffin-embedded (FFPE) from 130 samples.
Results: The rate of repeated tests in a total of buffy coat, FF and FFPE was 0%, 8%, and 34%, respectively. The accuracy of BRCA1/2 NGS testing was 100.0%, 99.9% and 99.9% in buffy coat, FFPE and FF, respectively. However, due to the presence of variant allele frequency (VAF) shifted heterozygous variants, tumor materials (FFPE and FF) showed lower sensitivity (95.5%-99.0%) than buffy coat (100%). Furthermore, FFPE showed 51.4% of the positive predictive value (PPV) on account of sequence artifacts. When performed in the post-filtration process, PPV was increased by approximately 20% in FFPE. Buffy coat showed 100% of sensitivity, specificity and accuracy in BRCA1/2 NGS test.
Conclusions: On the comparison of the analytical performance according to different sample types, the buffy coat was not affected by sequencing artifacts and VAF shifted variants. Therefore, the blood test should be given priority in detecting germline BRCA1/2 mutation, and tumor materials could be suitable to detect somatic mutations in OC patients without identifying germline BRCA1/2 mutation.

다운로드

(기관인증 필요)

초록보기

Objective: The purpose of this study was to analyze the impact of surgery of primary sites on stage IVB cervical cancer patients from a population-based database, the Surveillance, Epidemiology and End Results (SEER).
Methods: Propensity score matching was performed to minimize heterogeneity in patient between with-surgery group and without-surgery group. Clinicopathological characteristics were compared using the χ2 or Fisher's exact test. Survival analysis included the Kaplan-Meier method, log-rank test, and Cox proportional hazards model.
Results: Between 2010-2015, a total of 1,139 International Federation of Gynecology and Obstetrics (FIGO) stage IVB cervical cancer patients receiving chemoradiotherapy (CRT) were included in this retrospective study. Within post-matching cohort, the median duration of overall survival (OS) in stage IVB cervical cancer patients receiving CRT was 22 months. The overall 5-year survival rate was 25.7%. The increasing American Joint Committee on Cancer T stage (T1 vs. T2, p=0.033, hazard ratio [HR]=1.79, 95% confidence interval [CI]=1.05-3.05; T1 vs. T3, p=0.003, HR=2.20, 95% CI=1.31-3.67; T1 vs. T4, p=0.037, HR=2.75, 95% CI=1.06-7.12) and visceral metastasis (with vs. without, p=0.038, HR=1.60, 95% CI=1.03-2.49) was reported as independent risk factors of OS. Surgery of primary sites combined with CRT tended to prolong the survival of stage IVB cervical cancer patients (p<0.001, HR=0.36, 95% CI=0.21-0.61) compared with CRT, especially for patients without visceral metastasis (p=0.005, HR=0.31, 95% CI=0.14-0.70).
Conclusions: In conclusion, patients with stage IVB cervical cancer may achieve their best outcomes through CRT combined with surgery of primary sites. However, it deserves large scale prospective clinical trials to confirm.

12
권호별 보기
가장 많이 인용된 논문

(자료제공: 네이버학술정보)

가장 많이 인용된 논문
| | | |
1연안해역에서 석유오염물질의 세균학적 분해에 관한 연구

(2006)홍길동 외 1명심리학41회 피인용

다운로드

2미국의 비트코인 규제

(2006)홍길동심리학41회 피인용

다운로드

가장 많이 참고한 논문

(자료제공: 네이버학술정보)

가장 많이 참고한 논문

다운로드

2미국의 비트코인 규제

(2006)홍길동41회 피인용

다운로드

해당 간행물 관심 구독기관

원주교육문화관 대구보건대학교 우송대학교 한국방송통신대학교 연세대학교
 13
 10
 4
 3
 3
  • 1 원주교육문화관 (13건)
  • 2 대구보건대학교 (10건)
  • 3 우송대학교 (4건)
  • 4 한국방송통신대학교 (3건)
  • 5 연세대학교 (3건)
  • 6 한림대학교 강동성심병원 (3건)
  • 7 이화여자대학교 (2건)
  • 8 충북대학교 (1건)
  • 9 전주대학교 (1건)
  • 10 전남과학대학 (1건)

내가 찾은 최근 검색어

최근 열람 자료

맞춤 논문

보관함

내 보관함
공유한 보관함

1:1문의

닫기